Pacira BioSciences, Inc.
PCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,134,859 | $1,086,470 | $1,149,934 | $869,862 |
| - Cash | $147,589 | $300,484 | $283,610 | $276,774 |
| + Debt | $9,748 | $631,403 | $636,459 | $638,853 |
| Enterprise Value | $997,018 | $1,417,389 | $1,502,783 | $1,231,941 |
| Revenue | $179,516 | $181,099 | $168,923 | $187,253 |
| % Growth | -0.9% | 7.2% | -9.8% | – |
| Gross Profit | $145,238 | $140,233 | $134,617 | $147,367 |
| % Margin | 80.9% | 77.4% | 79.7% | 78.7% |
| EBITDA | $34,368 | $29,241 | $33,609 | $50,603 |
| % Margin | 19.1% | 16.1% | 19.9% | 27% |
| Net Income | $5,432 | -$4,847 | $4,812 | $16,041 |
| % Margin | 3% | -2.7% | 2.8% | 8.6% |
| EPS Diluted | 0.12 | -0.11 | 0.1 | 0.34 |
| % Growth | 209.1% | -210% | -70.6% | – |
| Operating Cash Flow | $60,834 | $12,012 | $35,459 | $33,132 |
| Capital Expenditures | -$3,870 | -$2,697 | -$8,548 | -$2,118 |
| Free Cash Flow | $56,964 | $9,315 | $26,911 | $31,014 |